A phase 2 study of lorigerlimab as monotherapy in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Lorigerlimab (Primary)
- Indications Gynaecological cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms LINNET
- 25 Mar 2025 New trial record
- 20 Mar 2025 According to MacroGenics media release, the Company anticipates enrolling up to 40 patients with PROC and up to 20 patients with CCGC in LINNET, which is expected to commence by mid-2025.